RESUMEN
A series of 4-(piperidin-4-yl)-1-hydroxypyrazole (4-PHP) 3- or 5-imidazolyl substituted analogues have been designed, synthesized, and characterized pharmacologically. All analogues showed binding affinities in the low micro- to low nanomolar range at native rat GABAA receptors and were found to be antagonists at the human α1ß2γ2s receptor. The structure-activity relationship of the compound series demonstrates distinct differences in size and architecture of previously discovered cavities in the vicinity of the 4-PHP scaffold in the orthosteric binding site.
Asunto(s)
Diseño de Fármacos , Pirazoles/metabolismo , Receptores de GABA-A/metabolismo , Animales , Sitios de Unión , Humanos , Modelos Moleculares , Pirazoles/química , Ratas , Relación Estructura-ActividadRESUMEN
We present a full-length α(1)ß(2)γ(2) GABA receptor model optimized for agonists and benzodiazepine (BZD) allosteric modulators. We propose binding hypotheses for the agonists GABA, muscimol and THIP and for the allosteric modulator diazepam (DZP). The receptor model is primarily based on the glutamate-gated chloride channel (GluCl) from C. elegans and includes additional structural information from the prokaryotic ligand-gated ion channel ELIC in a few regions. Available mutational data of the binding sites are well explained by the model and the proposed ligand binding poses. We suggest a GABA binding mode similar to the binding mode of glutamate in the GluCl X-ray structure. Key interactions are predicted with residues α(1)R66, ß(2)T202, α(1)T129, ß(2)E155, ß(2)Y205 and the backbone of ß(2)S156. Muscimol is predicted to bind similarly, however, with minor differences rationalized with quantum mechanical energy calculations. Muscimol key interactions are predicted to be α(1)R66, ß(2)T202, α(1)T129, ß(2)E155, ß(2)Y205 and ß(2)F200. Furthermore, we argue that a water molecule could mediate further interactions between muscimol and the backbone of ß(2)S156 and ß(2)Y157. DZP is predicted to bind with interactions comparable to those of the agonists in the orthosteric site. The carbonyl group of DZP is predicted to interact with two threonines α(1)T206 and γ(2)T142, similar to the acidic moiety of GABA. The chlorine atom of DZP is placed near the important α(1)H101 and the N-methyl group near α(1)Y159, α(1)T206, and α(1)Y209. We present a binding mode of DZP in which the pending phenyl moiety of DZP is buried in the binding pocket and thus shielded from solvent exposure. Our full length GABA(A) receptor is made available as Model S1.
Asunto(s)
Benzodiazepinas/farmacología , Agonistas de Receptores de GABA-A/farmacología , Simulación del Acoplamiento Molecular , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Humanos , Datos de Secuencia Molecular , Mutación , Receptores de GABA-A/genética , Alineación de SecuenciaRESUMEN
GABA(A) receptors (GABA(A)Rs) are ligand gated chloride ion channels that mediate overall inhibitory signaling in the CNS. A detailed understanding of their structure is important to gain insights in, e.g., ligand binding and functional properties of this pharmaceutically important target. Homology modeling is a necessary tool in this regard because experimentally determined structures are lacking. Here we present an exhaustive approach for creating a high quality model of the α(1)ß(2)γ(2) subtype of the GABA(A)R ligand binding domain, and we demonstrate its usefulness in understanding details of orthosteric ligand binding. The model was constructed by using multiple templates and by incorporation of knowledge from biochemical/pharmacological experiments. It was validated on the basis of objective energy functions, its ability to account for available residue specific information, and its stability in molecular dynamics (MD) compared with that of the two homologous crystal structures. We then combined the model with extensive structure-activity relationships available from two homologous series of orthosteric GABA(A)R antagonists to create a detailed hypothesis for their binding modes. Excellent agreement with key experimental data was found, including the ability of the model to accommodate and explain a previously developed pharmacophore model. A coupling to agonist binding was thereby established and discussed in relation to activation mechanisms. Our results highlight the importance of critical evaluation and optimization of each step in the homology modeling process. The approach taken here can greatly aid in increasing the understanding of GABA(A)Rs and related receptors where structural insight is limited and reliable models are difficult to obtain.
Asunto(s)
Simulación de Dinámica Molecular , Receptores de GABA-A/química , Secuencia de Aminoácidos , Animales , Sitios de Unión , Antagonistas de Receptores de GABA-A/farmacología , Humanos , Ligandos , Ratones , Datos de Secuencia Molecular , Unión Proteica , Receptores de GABA-A/metabolismo , Alineación de Secuencia , TorpedoRESUMEN
A 5-HT(2A) receptor model was constructed by homology modeling based on the ß(2)-adrenergic receptor and the G protein-bound opsin crystal structures. The 5-HT(2A) receptor model was transferred into an active conformation by an agonist ligand and a G(αq) peptide in four subsequent steered molecular dynamics (MD) simulations. The driving force for the transformation was the addition of several known intermolecular and receptor interhelical hydrogen bonds enforcing the necessary helical and rotameric movements. Subsquent MD simulations without constraints confirmed the stability of the activated receptor model as well as revealed new information about stabilizing residues and bonds. The active 5-HT(2A) receptor model was further validated by retrospective ligand screening of more than 9400 compounds, whereof 182 were known ligands. The results show that the model can be used in drug discovery for virtual screening and structure-based ligand design as well as in GPCR activation studies.
Asunto(s)
Subunidades alfa de la Proteína de Unión al GTP Gq-G11/metabolismo , Simulación de Dinámica Molecular , Receptor de Serotonina 5-HT2A/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/metabolismo , Sitios de Unión , Biología Computacional , Evaluación Preclínica de Medicamentos , Espacio Extracelular/metabolismo , Subunidades alfa de la Proteína de Unión al GTP Gq-G11/química , Humanos , Espacio Intracelular/metabolismo , Opsinas/metabolismo , Fragmentos de Péptidos/metabolismo , Fenetilaminas/química , Fenetilaminas/farmacología , Conformación Proteica , Receptor de Serotonina 5-HT2A/química , Receptores Adrenérgicos beta 2/metabolismo , Reproducibilidad de los Resultados , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Interfaz Usuario-ComputadorRESUMEN
Computational docking to nicotinic acetylcholine receptors (nAChRs) and other members of the Cys-loop receptor family is complicated by the flexibility of the so-called C-loop. As observed in the large number of published crystal structures of the acetylcholine binding protein (AChBP), a structural surrogate and homology modeling template for the nAChRs, the conformation of this loop is controlled by the ligand present in the binding pocket. As part of the development of a protocol for unbiased docking to the nAChRs, we here present the results of docking of ligands with known binding modes to an AChBP ensemble with systematic variations in C-loop closure generated via a series of targeted geometry optimizations. We demonstrate the ability to correctly predict binding modes for 12 out of 15 ligands and induced degrees of C-loop closure for 14 out of 15 ligands. Our approach holds a promising potential for structure based drug discovery within nAChRs and related receptors.
Asunto(s)
Proteínas Portadoras/química , Proteínas Portadoras/metabolismo , Estructura Secundaria de Proteína , Receptores Nicotínicos/química , Receptores Nicotínicos/metabolismo , Animales , Sitios de Unión , Simulación por Computador , Ligandos , Modelos Moleculares , Estructura Molecular , Unión Proteica , Reproducibilidad de los ResultadosRESUMEN
A series of substituted 1-hydroxypyrazole analogues of the GABA(A) receptor partial agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL) have been synthesized and pharmacologically characterized. Several of the analogues displayed K(i) in the low nanomolar range at the native GABA(A) receptors and potent antagonism of the alpha(1)beta(2)gamma(2) receptor. It appears that several regions situated in proximity to the core of the orthosteric binding site of the GABA(A) receptor are able to accommodate large hydrophobic substituents.
Asunto(s)
Antagonistas del GABA/síntesis química , Piperidinas/síntesis química , Pirazoles/síntesis química , Receptores de GABA-A/metabolismo , Animales , Línea Celular , Antagonistas del GABA/química , Antagonistas del GABA/farmacología , Inhibidores de Recaptación de GABA , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Técnicas In Vitro , Ligandos , Potenciales de la Membrana/efectos de los fármacos , Modelos Moleculares , Piperidinas/química , Piperidinas/farmacología , Pirazoles/química , Pirazoles/farmacología , Ratas , Relación Estructura-Actividad , Membranas Sinápticas/efectos de los fármacos , Membranas Sinápticas/fisiologíaRESUMEN
The novel ginkgolide analog ginkgolide X was characterized functionally at human glycine and gamma-aminobutyric acid type A receptors (GlyRs and GABA(A)Rs, respectively) in the fluorescence-based FLIPR(TM) Membrane Potential assay. The compound inhibited the signaling of all GABA(A)R subtypes included in the study with high nanomolar/low micromolar IC(50) values, except the rho 1 receptor at which it was a significantly weaker antagonist. Ginkgolide X also displayed high nanomolar/low micromolar IC(50) values at the homomeric alpha1 and alpha2 GlyRs, whereas it was inactive at the heteromeric alpha 1 beta and alpha 2 beta subtypes at concentrations up to 300 microm. Thus, the functional properties of the compound were significantly different from those of the naturally occurring ginkgolides A, B, C, J, and M but similar to those of picrotoxin. In a mutagenesis study the 6' M2 residues in the GlyR ion channel were identified as the primary molecular determinant of the selectivity profile of ginkgolide X, and a 6' M2 ring consisting of five Thr residues was found to be of key importance for its activity at the GABA(A)R. Conformational analysis and docking of low-energy conformations of the native ginkgolide A and ginkgolide X into a alpha1 GlyR homology model revealed two distinct putative binding sites formed by the 6' M2 residues together with the 2' residues and the 10' and 13' residues, respectively. Thus, we propose that the distinct functionalities of ginkgolide X compared with the other ginkgolides could arise from different flexibility and thus different binding modes to the ion channel of the anionic Cys-loop receptor.
Asunto(s)
Cisteína/química , Ginkgólidos/farmacología , Receptores de Glicina/metabolismo , Secuencia de Aminoácidos , Aniones , Sitios de Unión , Clonación Molecular , Relación Dosis-Respuesta a Droga , Ginkgólidos/química , Humanos , Concentración 50 Inhibidora , Potenciales de la Membrana , Datos de Secuencia Molecular , Picrotoxina/química , Unión Proteica , Receptores de Glicina/antagonistas & inhibidores , Homología de Secuencia de AminoácidoRESUMEN
Highly flexible proteins constitute a significant challenge in molecular docking within the field of drug design. Depending on the efficacy of the bound ligand, the ligand-binding domain (LBD) of the ionotropic glutamate receptor iGluR2 adopts markedly different degrees of domain closure due to large-scale domain movements. With the purpose of predicting the induced domain closure of five known iGluR2 partial to full agonists we performed a validation study in which normal mode analysis (NMA) was employed to generate a 25-membered ensemble of iGluR2 LBD structures with gradually changing domain closures, followed by accurate QM/MM docking to the ensemble. Based on the docking scores we were able to predict the correct optimal degree of closure for each ligand within 1-3 degrees deviation from the experimental structures. We demonstrate that NMA is a useful tool for reliable ensemble generation and that we are able to predict the ligand induced conformational change of the receptor through docking to such an ensemble. The described protocol expands and improves the information that can be obtained from computational docking when dealing with a flexible receptor.